Biosimilars could save $US billions

November 2014
PharmacoEconomics & Outcomes News;Nov2014, Vol. 716 Issue 1, p1
The article discusses a report from nonprofit research institute Rand Corp., which examines the cost savings potential of biosimilars or generic versions of biologicals used in treating various medical conditions until 2024 in the U.S.


Related Articles

  • Informed by the European Union Experience: What the United States Can Anticipate and Learn from the European Union's Regulatory Approach to Biosimilars. Gitter, Donna M. // Seton Hall Law Review;2011, Vol. 41 Issue 2, p559 

    The article focuses on how the European Union (EU) deals with the challenges that coincide biologic products with a view of its application in the U.S. It states that biologics are variable and are not manufactured as true generic equivalents compared to the generic version that traditional...

  • The Global Map of Biosimilars in 2014. Galbraith, Daniel // Pharmaceutical Processing;Apr2014, Vol. 29 Issue 4, p12 

    The article discusses the importance placed among pharmaceutical companies on biologics. Noted are the disadvantages of biologic drugs such as the length of time and the cost associated to development and production while indicated is one benefit, which is the protection among manufacturers on...

  • A run on brand x. Montague, Jim // H&HN: Hospitals & Health Networks;9/05/96, Vol. 70 Issue 17, p16 

    Cites a survey of international medicine doctors conducted by Hospital Research Associates which found that managed care plans' formularies cause the doctors to prescribe generic drugs more often. Forecast on generic drug prescription.

  • Pharmacists unwilling to substitute generics for some critical-dose drugs, despite payer policy...  // Hospital Formulary;Feb95, Vol. 30 Issue 2, p71 

    Reports survey findings that most pharmacists feel comfortable substituting generic drugs for brand-name drugs except for narrow-index drugs like Coumadin, Dilantin and Lanoxin. Reluctance to substitute a generic product in cases where a third-party payer required substitution; Consideration of...

  • Not exactly what the doctor ordered. Troy, Terry // Dermatology Times;Jan1999, Vol. 20 Issue 1, p14 

    Focuses on a survey of several pharmacies in Cleveland, Ohio conducted by `Dermatology Times' periodical after receiving complaints that pharmacists substitute generic and over-the-counter products for prescribed medicine. Response of a regional discount drug chain and three national drug...

  • Levetiracetam.  // Reactions Weekly;1/9/2010 Part 2 of 2, Issue 1283, p60 

    The article describes three cases of recurrent seizures after switching from branded to generic levetiracetam, an anticonvulsant.

  • 20 years ago.  // European Chemical News;2/3/2003, Vol. 78 Issue 2038, p21 

    Provides an overview of issues on the generic substitution of drugs in Great Britain in an effort to save money for the health service in January 1983. Estimation of savings from the generic substitution of drugs; Products recommended for generic substitution; Issue pointed out by drug makers.

  • FDA ATTACKS ANTIGENERIC LOBBYING EFFORT.  // H&HN: Hospitals & Health Networks;02/20/98, Vol. 72 Issue 4, p100 

    States that the United States Food and Drug Administration (FDA) defended the use of generic drugs, and criticized drugmakers for their efforts to prevent pharmacies from automatically substituting generic versions of brand names. Reference made to the drug, Coumadin; Why pharmacies are...

  • COMPETITION HEATS UP IN THE BIOLOGICS MARKET.  // Pharma Magazine;Jul/Aug2011, Vol. 7 Issue 4, p10 

    The article presents the author's insights on the emergence of biologic competition in the U.S. The author says that Big Pharma companies have invested on follow-on biologics to compete with multinational generic companies. He cites the impact of the U.S. biosimilar regulations to generics,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics